TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01763762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electrical pudendal nerve stimulation
Description: Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PFM training
Description: A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transvaginal ES
Description: A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
Study: NCT02041273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib isethionate (phase 1 and 2 studies)
Description: 125 mg palbociclib isethionate salt under overnight fasting conditions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib isethionate (phase 1 and 2 studies)
Description: 125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palbociclib commercial free base capsule
Description: 125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
Study: NCT02903862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindoula
Description: The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support \& assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DANA
Description: DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.

Intervention type: DEVICE
Group type: OTHER
Intervention: DANA
Description: DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
Study: NCT02259595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-07
Description: 500-1,500 mg oral capsules administered in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-07
Description: 500-1,500 mg oral capsules administered in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-07
Description: 500-1,500 mg oral capsules administered in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-07
Description: 500-1,500 mg oral capsules administered in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC
Description: 1,200mg NAC administered via oral capsule in single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo oral capsule
Study: NCT01331655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (BAY86-5300)
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP/L-5-MTHF (BAY98-7071)
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)
Description: Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
Study: NCT00811837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Intravenous infusion
Study: NCT02645799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABR-312
Description: administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (placebo)
Description: administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
Study: NCT00654732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bleomycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinblastine
Description: Given IV
Study: NCT04395547

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JointAlive™
Description: Combination herbal extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Combination placebo product
Study: NCT02966548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02480049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asmakast
Description: 1 tablet contains 10 mg of montelukast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Singulair
Description: 1 tablet contains 10 mg of montelukast
Study: NCT03473587

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview
Description: A lay health advisor will engage the subject in a motivational interview to promote the importance of colorectal cancer screening

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: A lay health advisor will provide the subject with a brochure promoting the importance of colorectal cancer screening
Study: NCT00184392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debridement or saline irrigation
Description: debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
Study: NCT03114865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab 9ug
Description: Cycle 1 - Days 1-7: 9 ug/day IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab 28 ug
Description: Cycle 1 - Days 8-28: 28 ug/day IV daily
Study: NCT04356144

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)
Description: Recombinant Human Thrombomodulin (TM) is added to the conventional TGA. When recombinant TM is added, the protein C system is fully activated and therefore the ETP obtained reflects both the anti- and procoagulant factors.
Study: NCT03165357

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Study: NCT03696069

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03055104

Intervention type: OTHER
Intervention: management of severe malnutrition
Description: multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
Study: NCT02973464

Intervention type: DRUG
Intervention: Valganciclovir
Description: Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
Study: NCT03114865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Cycle 2 - Days 1-28: 28 ug/day IV daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
Study: NCT03798210

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Study group split in two arms for experimental treatment with Lactobacillus reuteri or placebo.
Study: NCT02973464

Intervention type: DRUG
Intervention: Valganciclovir
Description: Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant

Intervention type: DRUG
Intervention: Ganciclovir
Description: intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
Study: NCT01028651

Intervention type: DRUG
Intervention: Treprostinil
Description: Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.~Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min.
Study: NCT03798210

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01447784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune HDM
Description: Intradermal injection 1 x 11 administrations 4 weeks apart
Study: NCT00536679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK163090 capsule, fasted
Description: GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK163090 capsule, fasted
Description: GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK163090 Tablet, fasted
Description: GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
Study: NCT02129114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReDura Onlay
Description: Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraGen
Description: Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
Study: NCT04863040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI intervention
Description: Each HIIT break will last approximately 5 minutes and will not require any specific materials. The structure of the HIIT-Rest will be as follows: 1' to describe the work to be done; 3' of work following the HIIT protocol: 6 repetitions of a functional movement such as squats, Jumping Jack or running on site for 10 at high intensity (85-90% of HR max) followed by 20 of recovery (65-75% of HR max); and 1' to perform a return to calm in order to lower the activation and prepare the student body to return to class activities. To increase the workload, and after evaluation of cardiorespiratory capacity, after 12 weeks of program, the HIIT protocol will be changed to 20 of high intensity work alternating with 10 of recovery.
Study: NCT01566734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cefazolin irrigation
Description: after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal Saline Irrigation
Description: after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
Study: NCT04621630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-235
Description: Active Drug
Study: NCT02143362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia induction,propofol, remifentanil ,cisatracurium
Description: 1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction,propofol, remifentanil ,cisatracurium
Description: 1. Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.~2. Intermittent injection cisatracurium (0.15mg/kg).~3. A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60.
Study: NCT04621630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-235
Description: Active Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-235
Description: Active Drug
Study: NCT02143362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia maintenance , propofol,remifentanil,cisatracurium
Description: 1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia maintenance , propofol,remifentanil,cisatracurium
Description: 1. Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.~2. Target Controlled Infusion remifentanil , targeted plasma concentrations are 3\~6ng/ml ,maintain heart rate to 60\~100 beats per minute and mean blood pressure to 70\~105 mmHg.~3. Intermittent injection cisatracurium (0.05mg/kg).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Awaken test
Description: 1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awaken test
Description: 1. Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.~2. In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .~3. Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.~4. Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .~5. Patients will receive initial anesthesia after finish awaken test.
Study: NCT04621630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study: NCT00329004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, up to 300 mg, once daily, up to 24 mos
Study: NCT01011777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDC
Description: After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10\^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10\^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
Study: NCT03695744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT00246753

Intervention type: DRUG
Group type: OTHER
Intervention: lapatinib ditosylate
Description: 1500 mg, daily until disease progression
Study: NCT03632200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The patients with a cancer of the VADS: in preoperative, all the patients will benefit from dietary advice during a multidisciplinary specific consultation (physiotherapist, dietician, nursing staff CMF). The accent will be put on the adaptations of the diet, the complementary nutritional contributions, the assistants in better to eat.~In post-operative, a dietetic consultation will be set up in 7 days at the post hospitalization and rate call phone at M1, M2, M4 and M5.~The undernourished patient will benefit besides a multidisciplinary consultation at the rate of a consultation a month during 6 months according to the same conditions
Study: NCT06239909

Intervention type: OTHER
Intervention: 24-h pad-weight test
Description: The patients will be asked to perform the 24-h pad-weight test

Intervention type: OTHER
Intervention: Patient Global Impression - Improvement Questionnaire
Description: The patient-reported outcome, as measured by PGI-I (Patient Global Impression - Improvement Questionnaire)
Study: NCT02843334

Intervention type: BIOLOGICAL
Intervention: Dried blood spot (DBS) sampling
Description: DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
Study: NCT03695991

Intervention type: PROCEDURE
Intervention: percutaneous nephrostomy
Description: The percutaneous nephrostomy will be done under sonographic or fluoroscopic guidance. Establishment of intravenous access and antibiotics will be performed half an hour prior to procedure particularly in patients presenting with urinary tract infection. The procedure will be done under local anesthesia but general anesthesia may be used for uncooperative patients. percutaneous nephrostomy will be performed in the prone position, however, in case of relative contraindication to prone position
Study: NCT01884532

Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.

Intervention type: DEVICE
Intervention: ASR-XL Metal-on-Metal
Description: All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
Study: NCT04384783

Intervention type: DRUG
Intervention: growth hormone
Description: growth hormone was adjuvanted 2IU/d from previous menstrual period for about six weeks.